Advertisement
Advertisement
U.S. markets open in 8 hours 32 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Kadant Inc. (KAI)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
194.36+1.19 (+0.62%)
At close: 04:00PM EDT
194.36 -0.57 (-0.29%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close193.17
Open195.28
Bid0.00 x 1000
Ask0.00 x 900
Day's Range191.56 - 195.43
52 Week Range168.43 - 240.47
Volume42,053
Avg. Volume39,180
Market Cap2.267B
Beta (5Y Monthly)1.18
PE Ratio (TTM)20.27
EPS (TTM)9.59
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & Yield1.04 (0.54%)
Ex-Dividend DateJul 13, 2022
1y Target Est218.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-9% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for KAI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kadant Inc
    Analyst Report: Danaher CorporationIn 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
Advertisement
Advertisement